Personalized Anti-Cancer Vaccine Pivotal Phase III Results To Be Presented At ASCO Plenary Session

May 25, 2009

Biovest International, Inc. (Other OTC:BVTI), a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc. (Other OTC:ABPIQ), announced that BiovaxID, Biovest’s personalized anti-cancer vaccine targeting B-cell blood cancers, will be featured in an oral presentation during the Plenary Session at the American Society of Clinical Oncology (ASCO) Annual Meeting on Sunday, May 31st, 2009 in Orlando, Florida.

Stephen J. Schuster, M.D., Associate Professor of Medicine at the Abramson Cancer Center of the University of Pennsylvania, will deliver the BiovaxID presentation titled, “Idiotype Vaccine Therapy (BiovaxID) in Follicular Lymphoma in First Complete Remission: Phase III Clinical Trial Results.”
Read the rest of this entry »


Oregon House Approves Bill Mandating Insurance Coverage Of HPV Vaccine

April 22, 2009

The Oregon House on Wednesday voted 48-12 to pass a bill (H.B. 2794) that would require state-regulated insurance plans to cover the cost of the human papillomavirus vaccine for girls and women, the Oregonian reports. The vaccine, which FDA approved in 2006 for girls and young women ages nine to 26, protects against certain strains of HPV that cause cervical cancer. The bill does not require that people receive the vaccine, and its coverage requirements do not apply to “large companies that are self-insured.”
Read the rest of this entry »

Intercell Reports Study Showing Japanese Encephalitis Vaccine Is Safe AndImmunogenic In Children At ASTMH Meeting In New Orleans

January 15, 2009

Intercell AG (VSE: ICLL) today presented results of a clinical study of its Japanese Encephalitis vaccine IC51 in children at the American Society for Tropical Medicine and Hygiene Annual Meeting in New Orleans. The clinical study in children from 1 to 3 years of age demonstrated excellent immunogenicity with a safety profile similar to placebo.

The company also presented follow‐up data demonstrating the safety of IC51 in vaccines aged 18 years and older, followed for at least 6 months and for 24 months in a long‐term follow‐up study. In addition, Novartis Vaccines, which will market and distribute the vaccine in the U.S., Europe and other parts of the world, hosted a symposium at the meeting that gave an overview of the risk of the virus in tourists, expatriates and military personnel.
Read the rest of this entry »

Researchers At Global HIV/AIDS Vaccine Conference Express Concerns About Funding Levels

January 8, 2009

Experts at the AIDS Vaccine 2008 conference in Cape Town, South Africa, on Tuesday expressed concerns that the current global economic situation could damage funding for AIDS research and vaccine development, the AP/Los Angeles Times reports. The economic situation has “added to the gloom among experts deeply frustrated by … setbacks” in HIV/AIDS vaccine research, according to the AP/Times. There also are concerns that some groups that are large contributors to health and international development initiatives could reduce funding in light of the economic situation, the AP/Times reports.
Read the rest of this entry »

Supplement Launched At Successful Influenza Conference: Milestone Influenza Publication By Elsevier Journal Vaccine

January 8, 2009

Last month during an influenza conference organized by the European Scientific Working Group on influenza (ESWI), the Elsevier journal Vaccine released a supplement dedicated to influenza vaccines ( This publication provides a comprehensive, state-of-the-art overview on influenza vaccines and was supported by the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA).
Read the rest of this entry »

HPV Vaccine Requirement For Female Immigrants Discriminatory, Advocates Say

January 6, 2009

Some immigration and women’s rights advocacy groups are claiming that a new requirement for female immigrants to receive the human papillomavirus vaccine is discriminatory, the Dallas Morning News reports. The requirement, which applies to female immigrants ages 11 to 26 seeking permanent residence, went into effect on July 1. The vaccine, approved by FDA two years ago and recommended by CDC’s Advisory Committee on Immunization Practices, prevents transmission of HPV strains responsible for 70% of cervical cancer and 90% of genital warts.
Read the rest of this entry »

NPR’s ‘Morning Edition’ Examines Parents’ Concerns About HPV Vaccine

January 4, 2009

NPR’s “Morning Edition” on Thursday examined how uneasiness among some parents about having their adolescent girls receive the human papillomavirus vaccine, which is recommended for girls ages 11 to 12, is contributing to low vaccination rates.

NPR reports that the CDC age recommendations for the HPV vaccine were aimed at vaccinating girls before they become sexually active and have the chance to contract HPV. According to CDC, as of late 2007 about 20% of girls younger than age 18 had received the HPV vaccine, which can protect against cervical cancer. Experts say the low numbers largely can be attributed to parents who doubt that their child is sexually active, as well as a mistrust of vaccines and concerns about cost, with the required series running more than $400.
Read the rest of this entry »